Show simple item record

AuthorShurrab, Farah M.
AuthorAl-Sadeq, Duaa W.
AuthorAbou-Saleh, Haissam
AuthorAl-Dewik, Nader
AuthorElsharafi, Amira E.
AuthorHamaydeh, Fatima M.
AuthorAbo Halawa, Bushra Y.
AuthorJamaleddin, Tala M.
AuthorAbdul Hameed, Huda M.
AuthorNizamuddin, Parveen B.
AuthorAmanullah, Fathima Humaira
AuthorDaas, Hanin I.
AuthorAbu-Raddad, Laith J.
AuthorNasrallah, Gheyath K.
Available date2022-05-11T07:08:33Z
Publication Date2022-02-01
Publication NameVaccines
Identifierhttp://dx.doi.org/10.3390/vaccines10020191
CitationShurrab, F.M.; Al-Sadeq, D.W.; Abou-Saleh, H.; Al-Dewik, N.; Elsharafi, A.E.; Hamaydeh, F.M.; Halawa, B.Y.A.; Jamaleddin, T.M.; Hameed, H.M.A.; Nizamuddin, P.B.; Amanullah, F.H.; Daas, H.I.; Abu-Raddad, L.J.; Nasrallah, G.K. Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative Study. Vaccines 2022, 10, 191. https://doi.org/10.3390/vaccines10020191
URIhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85124042840&origin=inward
URIhttp://hdl.handle.net/10576/30830
AbstractThe currently authorized mRNA COVID-19 vaccines, Pfizer-BNT162b2 and Moderna-mRNA-1273, offer great promise for reducing the spread of the COVID-19 by generating protective immunity against SARS-CoV-2. Recently, it was shown that the magnitude of the neutralizing antibody (NAbs) response correlates with the degree of protection. However, the difference between the immune response in naïve mRNA-vaccinated and previously infected (PI) individuals is not well studied. We investigated the level of NAbs in naïve and PI individuals after 1 to 26 (median = 6) weeks of the second dose of BNT162b2 or mRNA-1273 vaccination. The naïve mRNA-1273 vaccinated group (n = 68) generated significantly higher (~2-fold, p ≤ 0.001) NAbs than the naïve BNT162b2 (n = 358) group. The P -vaccinated group (n = 42) generated significantly higher (~3-fold; p ≤ 0.001) NAbs levels than the naïve-BNT162b2 (n = 426). Additionally, the older age groups produced a significantly higher levels of antibodies than the young age group (>30) (p = 0.0007). Our results showed that mRNA-1273 generated a higher NAbs response than the BNT162b2 vaccine, and the PI group generated the highest level of NAbs response regardless of the type of vaccine.
SponsorThis work was made possible by grant number UREP28-173-3-057 from the Qatar National Research Fund (a member of Qatar Foundation). The statements made herein are solely the responsibility of the authors.
Languageen
PublisherMDPI
SubjectModerna-mRNA-1273
Neutralizing antibodies
Pfizer-BNT162b2
SARS-CoV-2
Vaccine
TitleAssessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative Study
TypeReport
Issue Number2
Volume Number10
ESSN2076-393X
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record